New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Heatwurx Inc.

PCSA

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

1.67 0.03 −1.76%
Market cap
$4.8M
P/E
n/m
Fwd P/E FY16e
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
0.4×
Payout ratio
—

Ratios over time Q4 FY25 to Q3 FY26

Returns on capital

ROIC was 0.0% in Q3 FY26, the highest of these four quarters. ROE, at 220.1%, is far above it because equity is small against the capital the business uses.

ROEROIC
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
ROE−373.0%−465.0%−464.2%220.1%
ROIC−21857.0%−1064.3%0.0%0.0%

Debt

Net debt is 0.98× a year’s EBITDA. Debt is 0.00× equity.

Debt / equityNet debt / EBITDA
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Debt / equity0.0×0.0×0.0×0.0×
Net debt / EBITDA1.5×0.5×0.1×1.0×
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
97.70 0.87 0.98 2.54
Net Debt/EBITDA
0.98 0.08 0.51 1.50
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(1.74) (0.66) (1.56) (2.86)
Book value per Share
(60.99) (0.12) 0.97 4.26
Free Cash Flow
(5.18) (1.81) (4.09) (3.75)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 18 Nov 2026